These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 21450501)

  • 1. Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults.
    Murray RD; Randeva HS; Lewandowski KC; Komorowski J; Lawrance JA; Adams JE; Shalet SM
    Growth Horm IGF Res; 2011 Apr; 21(2):96-101. PubMed ID: 21450501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals.
    Randeva HS; Lewandowski KC; Komorowski J; Murray RD; O'Callaghan CJ; Hillhouse EW; Stepien H; Shalet SM
    Circulation; 2004 May; 109(20):2405-10. PubMed ID: 15123527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs.
    Gentilini F; Calzolari C; Turba ME; Agnoli C; Fava D; Forni M; Bergamini PF
    Leuk Res; 2005 Nov; 29(11):1263-9. PubMed ID: 15893373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency].
    Szczepańska-Kostro J; Kowalewski M; Urban M; Gardziejczyk M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(4):257-60. PubMed ID: 17239302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
    Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
    Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
    Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of growth hormone status on circulating levels of vascular growth factors.
    Silha JV; Krsek M; Hana V; Marek J; Weiss V; Jezkova J; Rosicka M; Jarkovska Z; Murphy LJ
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):79-86. PubMed ID: 15963066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of high-sensitivity C-reactive protein and soluble markers of vascular endothelial cell activation in growth hormone-deficient adolescents.
    Lanes R; Marcano H; Villaroel O; Gunczler P; Morillo E; Paoli M; Perez M; Maulino N; Palacios A
    Horm Res; 2008; 70(4):230-5. PubMed ID: 18772596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
    Laack E; Scheffler A; Burkholder I; Boeters I; Andritzky B; Schuch G; Görn M; Vohwinkel G; Edler L; Fiedler W; Hossfeld DK
    Lung Cancer; 2005 Oct; 50(1):51-8. PubMed ID: 15992959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF-1, IGFBP-3, VEGF and MMP-9 levels and their potential relationship with renal functions in patients with compensatory renal growth.
    Yildiz B; Kural N; Colak O; Ak I; Akcar N
    Clin Physiol Funct Imaging; 2008 Mar; 28(2):107-12. PubMed ID: 18093232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal calcium absorption and bone metabolism in young adult men with childhood-onset growth hormone deficiency.
    de Boer H; Blok GJ; Popp-Snijders C; Sips A; Lips P; van der Veen E
    J Bone Miner Res; 1998 Feb; 13(2):245-52. PubMed ID: 9495517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol].
    Zhao ZF; Lü RR; Huo R; Fu HB; Xu GQ
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2011 Sep; 27(5):359-61. PubMed ID: 22259987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid profiles in adults with growth hormone (GH) deficiency before and during GH replacement therapy.
    Fernholm R; Thoren M; Hoybye C; Anderstam B; Pernow Y; Saaf M; Hall K
    Growth Horm IGF Res; 2009 Jun; 19(3):206-11. PubMed ID: 18990596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.
    Deepak D; Daousi C; Javadpour M; Clark D; Perry Y; Pinkney J; Macfarlane IA
    Growth Horm IGF Res; 2010 Jun; 20(3):220-5. PubMed ID: 20185347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma total homocysteine concentrations in adults with growth hormone (GH) deficiency: effects of GH replacement.
    Lewandowski KC; Murray RD; Drzewoski J; O'Callaghan CJ; Czupryniak L; Hillhouse EW; Shalet SM; Randeva HS
    Mol Genet Metab; 2003 Nov; 80(3):330-7. PubMed ID: 14680980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GH replacement reduces increased lipid peroxidation in GH-deficient adults.
    Karbownik-Lewinska M; Kokoszko A; Lewandowski KC; Shalet SM; Lewinski A
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):957-64. PubMed ID: 18031310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of gelatinases (matrix metalloproteinases 2 and 9), vascular endothelial growth factor and endostatin on clinicopathological behaviour of rectal cancer.
    Cavdar Z; Canda AE; Terzi C; Sarioglu S; Fuzun M; Oktay G
    Colorectal Dis; 2011 Feb; 13(2):154-60. PubMed ID: 19888958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
    Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
    Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhinovirus upregulates matrix metalloproteinase-2, matrix metalloproteinase-9, and vascular endothelial growth factor expression in nasal polyp fibroblasts.
    Wang JH; Kwon HJ; Jang YJ
    Laryngoscope; 2009 Sep; 119(9):1834-8. PubMed ID: 19572270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.